| RRC ID |
77863
|
| Author |
Toma T, Miyakawa N, Tateishi M, Todaka M, Kondo T, Fujita M, Otsuka M, Araki E, Tateishi H.
|
| Title |
An ADAM17 selective inhibitor promotes glucose uptake by activating AMPK.
|
| Journal |
J Pharmacol Sci
|
| Abstract |
AMPK activation promotes glucose and lipid metabolism. Here, we found that our previously reported ADAM17 inhibitor SN-4 activates AMPK and promotes membrane translocation and sugar uptake of GLUT4. AMPK inhibitor dorsomorphin reversed this effect of SN-4, confirming that the effect is mediated by AMPK activation. In addition, SN-4 inhibited lipid accumulation in HepG2 under high glucose conditions by promoting lipid metabolism and inhibiting lipid synthesis. Although lactic acidosis is a serious side effect of biguanides such as metformin, SN-4 did not affect lactate production. Furthermore, SN-4 was confirmed to inhibit the release of TNF-α, a causative agent of insulin resistance, from adipocytes. In diabetes treatment, it is important to not only regulate blood sugar levels but also prevent complications. Our findings reveal the therapeutic potential of SN-4 as a new antidiabetic drug that can also help prevent future complications.
|
| Volume |
154(1)
|
| Pages |
37-46
|
| Published |
2024-1-1
|
| DOI |
10.1016/j.jphs.2023.11.005
|
| PII |
S1347-8613(23)00067-1
|
| PMID |
38081682
|
| MeSH |
AMP-Activated Protein Kinases* / metabolism
Glucose / metabolism
Glucose Transporter Type 4
Hypoglycemic Agents / pharmacology
Lipids
Metformin* / pharmacology
|
| IF |
2.835
|
| Resource |
| Human and Animal Cells |
Hep G2(RCB1648) |
